Matthew Gall - 01 May 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Chief Financial Officer
Issuer ticker: TNGX
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2026, 19:46:28 UTC
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Matthew Gall filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 05 May 2026.

Key facts

This page summarizes Matthew Gall's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 May 2026, 19:46.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816194 Primary reporting owner

Gall Matthew

Relationship: Chief Financial Officer
Address: C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 05 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value
Shares: +40,000
Change %
Price: $0.000000^*
Shares after: 40,000
Date: 01 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +240,000
Change %
Price: $0.000000^*
Shares after: 240,000
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 240,000
Exercise price: $20.98
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F2

This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.